Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE ‐HF trial

ConclusionsWe studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the best clinical model: soluble suppression of tumorigenicity 2 (primary outcome), Notch ‐3 (CV and all‐cause death), and GDF‐15 (all‐cause death).

Source: ESC Heart Failure - January 16, 2020 Category: Cardiology Authors: Jo ão Pedro Ferreira, Kévin Duarte, Holger Woehrle, Martin R. Cowie, Karl Wegscheider, Christiane Angermann, Marie‐Pia d'Ortho, Erland Erdmann, Patrick Levy, Anita K. Simonds, Virend K. Somers, Helmut Teschler, Patrick Rossignol, Wolfgang Tags: Original Research Article Source Type: research